ViaCyte Gets $80M Series D For Pursuit of Diabetes Cure
Wednesday, December 5, 2018
Paul Laikind is the CEO of ViaCyte, a San Diego company flying high with a recent $80 million Series D round. Photo courtesy of ViaCyte
ViaCyte recently hauled in an $80 million Series D round to advance therapies that the company called a potential “functional cure” for Type 1 diabetes patients...
Take 1 minute to subscribe and you'll get this story immediately, plus:
Already a subscriber? Sign in
- 52 weekly issues
- Subscriber-only digital content every business day, plus full access to SDBJ.com archives
- Book of Lists — the most comprehensive business resource in San Diego
- San Diego 500 — influential business leaders you need to know